4:16 PM
 | 
Jan 25, 2018
 |  BioCentury  |  Finance

Weighing exchanges

How diabetes play Hua is choosing between Hong Kong and the U.S. for its IPO

Hua Medicine Ltd. is weighing the merits of pursuing an IPO in Hong Kong versus the U.S. ahead of the expected launch of lead candidate dorzagliatin in China.

The Shanghai company’s financing strategy will be led by EVP and CFO George Lin, who joined Hua in December. He was previously head of consumer, retail and healthcare investment banking for Asia Pacific and head of investment banking coverage for Hong Kong and Taiwan at Bank of America Corp. (NYSE:BAC).

Lin told BioCentury...

Read the full 393 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >